国家医保局：把较高质量风险产品排除在集采之外

智通财经2025-02-10

2018年以来的持续实践，既让集采政策和集采药品得到了临床检验，也让我国患者的主流用药实现了从“未过评仿制药”到“过评仿制药”的跨越。在进一步完善集采政策方面，国家医保局表示，将广泛了解药品接受日常监管情况，把存在较高质量风险的产品排除在集采之外。对于预计投标企业数量超过一定规模、竞争比较激烈的品种，提前进行强竞争预警，提示企业慎重决策，科学投标，理性报价。对偏离度高的最低报价予以重点关注，并请...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2510488390?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-10 10:43","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2510488390","market":"sh","top_or_hot":-1,"title":"国家医保局：把较高质量风险产品排除在集采之外","media":"智通财经","content":"<div>\n<p>2018年以来的持续实践，既让集采政策和集采药品得到了临床检验，也让我国患者的主流用药实现了从“未过评仿制药”到“过评仿制药”的跨越。在进一步完善集采政策方面，国家医保局表示，将广泛了解药品接受日常监管情况，把存在较高质量风险的产品排除在集采之外。对于预计投标企业数量超过一定规模、竞争比较激烈的品种，提前进行强竞争预警，提示企业慎重决策，科学投标，理性报价。对偏离度高的最低报价予以重点关注，并请...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210104444961d5cc5&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国家医保局：把较高质量风险产品排除在集采之外</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国家医保局：把较高质量风险产品排除在集采之外\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-10 10:43 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210104444961d5cc5&s=b><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2018年以来的持续实践，既让集采政策和集采药品得到了临床检验，也让我国患者的主流用药实现了从“未过评仿制药”到“过评仿制药”的跨越。在进一步完善集采政策方面，国家医保局表示，将广泛了解药品接受日常监管情况，把存在较高质量风险的产品排除在集采之外。对于预计投标企业数量超过一定规模、竞争比较激烈的品种，提前进行强竞争预警，提示企业慎重决策，科学投标，理性报价。对偏离度高的最低报价予以重点关注，并请...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210104444961d5cc5&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688506","symbol_name":"百利天恒","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210104444961d5cc5&s=b","article_id":"2510488390","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210104444961d5cc5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2510488390","pubTimestamp":1739155385,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2018年以来的持续实践，既让集采政策和集采药品得到了临床检验，也让我国患者的主流用药实现了从“未过评仿制药”到“过评仿制药”的跨越。在进一步完善集采政策方面，国家医保局表示，将广泛了解药品接受日常监管情况，把存在较高质量风险的产品排除在集采之外。对于预计投标企业数量超过一定规模、竞争比较激烈的品种，提前进行强竞争预警，提示企业慎重决策，科学投标，理性报价。对偏离度高的最低报价予以重点关注，并请企业及时公开回应有关关切。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600062":"华润双鹤","600079":"ST人福","600196":"复星医药","600200":"*ST苏吴","600216":"浙江医药","600267":"海正药业","600276":"恒瑞医药","600380":"健康元","600420":"国药现代","600488":"津药药业","600513":"联环药业","600521":"华海药业","600613":"神奇制药","600624":"ST复华","600664":"哈药股份","600774":"汉商集团","600789":"鲁抗医药","600812":"华北制药","600851":"海欣股份","601089":"福元医药","603168":"莎普爱思","603207":"小方制药","603229":"奥翔药业","603351":"威尔药业","603367":"辰欣药业","603520":"司太立","603538":"美诺华","603669":"灵康药业","603676":"卫信康","603707":"健友股份","603811":"诚意药业","605116":"奥锐特","605177":"东亚药业","605507":"国邦医药","688062":"迈威生物","688076":"ST诺泰","688091":"上海谊众","688117":"圣诺生物","688166":"博瑞医药","688176":"亚虹医药","688189":"南新制药","688192":"迪哲医药","688197":"首药控股","688221":"前沿生物","688235":"百济神州","688247":"宣泰医药","688266":"泽璟制药","688302":"海创药业","688321":"微芯生物","688356":"键凯科技","688373":"盟科药业","688382":"益方生物","688428":"诺诚健华","688505":"复旦张江","688506":"百利天恒","688513":"苑东生物","688553":"汇宇制药","688566":"吉贝尔","688578":"艾力斯","688602":"康鹏科技","688658":"悦康药业","688690":"纳微科技","688758":"赛分科技","688799":"华纳药厂","BK0060":"抗癌","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0239":"医药制造","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK0188":"融资融券","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0196":"行业龙头","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","BK0012":"证金概念","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0183":"MSCI概念","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK0028":"国家队"},"translate_title":"National Healthcare Security Administration: Exclude higher-quality risk products from centralized procurement","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600062":0.9,"600079":0.9,"600196":0.9,"600200":0.9,"600216":0.9,"600267":0.9,"600276":0.9,"600380":0.9,"600420":0.9,"600488":0.9,"600513":0.9,"600521":0.9,"600613":0.9,"600624":0.9,"600664":0.9,"600774":0.9,"600789":0.9,"600812":0.9,"600851":0.9,"601089":0.9,"603168":0.9,"603207":0.9,"603229":0.9,"603351":0.9,"603367":0.9,"603520":0.9,"603538":0.9,"603669":0.9,"603676":0.9,"603707":0.9,"603811":0.9,"605116":0.9,"605177":0.9,"605507":0.9,"688062":0.9,"688076":0.9,"688091":0.9,"688117":0.9,"688166":0.9,"688176":0.9,"688189":0.9,"688192":0.9,"688197":0.9,"688221":0.9,"688235":0.9,"688247":0.9,"688266":0.9,"688302":0.9,"688321":0.9,"688356":0.9,"688373":0.9,"688382":0.9,"688428":0.9,"688505":0.9,"688506":0.9,"688513":0.9,"688553":0.9,"688566":0.9,"688578":0.9,"688602":0.9,"688658":0.9,"688690":0.9,"688758":0.9,"688799":0.9},"content_text":"2018年以来的持续实践，既让集采政策和集采药品得到了临床检验，也让我国患者的主流用药实现了从“未过评仿制药”到“过评仿制药”的跨越。在进一步完善集采政策方面，国家医保局表示，将广泛了解药品接受日常监管情况，把存在较高质量风险的产品排除在集采之外。对于预计投标企业数量超过一定规模、竞争比较激烈的品种，提前进行强竞争预警，提示企业慎重决策，科学投标，理性报价。对偏离度高的最低报价予以重点关注，并请企业及时公开回应有关关切。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2510488390","isCrawlerRequest":true}